Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women

Osteoporosis International

Volumn 19, Issue 8, 2008, Pages 1153-1160

  Delmas, P D ^a,g   Davis, S R ^b   Hensen, J ^c   Adami, S ^d   Van Os, S ^e   Nijland, E A ^f  

^a UNIVERSITÉ DE LYON   (France)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF VERONA   (Italy)

^e Global Clinical Research   (Netherlands)

^f Rugpoli Twente ^*  (Netherlands)

^g EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bone mineral density; Menopause; Osteoporosis; Raloxifene; Tibolone

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; RALOXIFENE; TIBOLONE; VITAMIN D;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITOMETRY; BREAST CANCER; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSTONIA; ENDOMETRIAL DISEASE; ENDOMETRIUM POLYP; FEMALE; HIP; HUMAN; HYDROMETRA; HYPERHIDROSIS; HYPERTENSION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENINGIOMA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; MUSCLE SPASM; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; VAGINA BLEEDING; WEIGHT GAIN;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NORPREGNENES; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 46649096223     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0545-3     Document Type: Article

References (39)

1. European Foundation for Osteoporosis and the National Osteoporosis Foundation (1997) Consensus Development Statement: Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7:1-6
2. Melton LJ 3rd, Chrischilles EA, Cooper C et al (1992) Perspective.How many women have osteoporosis? J Bone Miner Res 7:1005-1010
3. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
4. Leibson CL, Tosteson AN, Gabriel SE et al (2002) Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 50:1644-1650
5. Wells G, Tugwell P, Shea B et al, for the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529-539
6. Cauley JA, Robbins J, Chen Z et al, for the Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290:1729-1738
7. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
8. Kloosterboer HJ (2004) Tissue-selectivity: the mechanism of action of tibolone. Maturitas 48(Suppl 1):S30-S40
9. Ederveen AGH, Kloosterboer HJ (2001) Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 16:1651-1657
10. Thiebaud D, Bigler JM, Renteria S et al. A 3-year study of prevention of postmenopausal bone loss: conjugated estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric 1:202-210
11. Roux C, Pelissier C, Fechtenbaum J et al (2002) Randomized, double-blind, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis Int 13:241-248
12. Lippuner K, Haenggi W, Birkhaeuser MH et al (1997) Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-oestradiol and dydrogesterone. J Bone Miner Res 12:806-812
13. Milner M, Harrison RF, Gilligan E et al (2000) Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause 7:327-333
14. Rymer J, Robinson J, Fogelman I (2002) Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 5:390-398
15. Berning B, Kuijk CV, Kuiper JW et al (1996) Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 19:395-399
16. Pavlov PW, Ginsburg J, Kicovic PM et al (1999) Double-blind, placebo controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 13:230-237
17. Bjarnason NH, Bjarnason K, Haarbo J et al (1996) Tibolone prevention of bone loss in late postmenopausal women. J Clin Endocronol Metab 81:2419-2422
18. Bjarnason BH, Bjarnason K, Hassager C et al (1997) The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 20:151-155
19. Gallagher JC, Baylink DJ, Freeman R et al (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86:4717-4726
20. Gambacciani M, Ciaponi M, Cappagli B et al (2004) A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol 18:9-16
21. Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
22. Weinstein RS, Parfitt AM, Marcus R et al (2003) Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 14:814-822
23. Lufkin EG, Whitaker MD, Nickelsen T et al (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754
24. Johnston CC Jr, Bjarnason NH, Cohen FJ et al (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450
25. Meunier PJ, Vignot E, Garnero P et al (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10:330-336
26. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
27. Delmas PD, Ensrud KE, Adachi JD et al, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
28. Cummings SR, Delmas PD, Bilezikian JP et al (2006) The effects of tibolone in older women with osteoporosis: preliminary results from the LIFT trial. Osteoporos Int 17:952-953
29. Cummings SR (2006) LIFT study is discontinued. Letter to the editor. BMJ 332:667
30. The North American Menopause Society (2006) Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 13:340-367
31. Studd J, Arnala I, Kicovic PM et al (1998) A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 92:574-579
32. Geusens P, Dequeker J, Gielen J et al (1991) Non-linear increase in vertebral density induced by a synthetic steroid (org OD14) in women with established osteoporosis. Maturitas 13:155-162
33. Dören M, Nilsson J-Å, Johnell O (2003) Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 18:1737-1746
34. Siris ES, Harris ST, Eastell R et al, for the Continuing Outcomes Relevant to Evista (CORE) Investigators (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514-1524
35. Delmas PD, Genant HK, Crans GG et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522-532
36. Frolik CA, Bryant HU, Black EC et al (1996) Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen and alendronate. Bone 18:621-627
37. Heaney RP, Draper MW (1997) Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:3425-3429
38. Kloosterboer HJ, Ederveen AGH (2003) Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments. J Steroid Biochem Mol Biol 83:157-165
39. Allen MR, Iwata K, Sato M et al (2006) Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 39:1130-1135